Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-14
2006-03-14
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000, C546S112000, C514S303000
Reexamination Certificate
active
07012080
ABSTRACT:
This invention provides a compound of the formula (I):or a pharmaceutically acceptable salt thereof, whereinR1represents a hydrogen atom or a halogen atom;R2represents a methyl group or an ethyl group;R3represents a branched alkyl group having from 3 to 6 carbon atoms or an alkyl group having from 3 to 6 carbon atoms substituted by an alkoxy group having from 1 to 6 carbon atoms;with the proviso that when the terminal carbon atom of said alkyl group of R3is substituted by said alkoxy group, said alkyl group is a branched alkyl group.These compounds have 5-HT4receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
REFERENCES:
patent: 5137893 (1992-08-01), Becker et al.
patent: 5196547 (1993-03-01), Becker et al.
patent: 5219850 (1993-06-01), Becker et al.
patent: 5260303 (1993-11-01), Becker et al.
patent: 5434161 (1995-07-01), Becker et al.
patent: 5591749 (1997-01-01), Becker et al.
patent: 5604239 (1997-02-01), Becker et al.
patent: 6624162 (2003-09-01), Uchida et al.
patent: 0504679 (1992-09-01), None
patent: 0274867 (1994-04-01), None
patent: H01258674 (1989-10-01), None
patent: H02643274 (1989-10-01), None
patent: 2001 006877 (2001-01-01), None
patent: WO 9215593 (1992-09-01), None
patent: WO 9408998 (1994-04-01), None
patent: WO 9605166 (1996-02-01), None
patent: WO 9727852 (1997-08-01), None
patent: WO 9738665 (1997-10-01), None
patent: WO 9950247 (1999-10-01), None
patent: WO 0105763 (2001-01-01), None
Barnes et al. Neuropharmacology 38(1999) 1083-1185, 1118-1125.
Dumuis, et al., “A 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205 930”,European Journal of Pharmacology, 146 (1988), 187-188.
Dumuis, et al., “The gastrointestinal prokinetic benzamide derivatives are agonists al the non-classican 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons”,Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340: 403-410.
Bockaert, et al., “The 5-HT4 receptor: a place in the sun”,TiPs, 1992, 13, 141-145.
Ford, A.P.D.W., et al., “The 5-HT4Receptor”,Med. Res. Rev., 1993, 13, 633-662.
Gullikson, G.W., et al., “Gastrointestinal Motility Responses to the S and R Enantiomers of Zacopride, a 5-HT4 Agonist and 5-HT3 Antagonist”,Drug Dev. Res., 1992, 26, 405-417.
Eglen, et al., “Central 5-HT4receptors”,TiPs, 1995, 16, 391-398.
Bockaert, Jr., et al., “Receptors Potential Therapeutic Implications in Neurology and Psychiatry”,CNS Drugs, 1(1):6-15, 1994.
Romanelli, M.N., et al., “Synthesis and Biological Activity of a Series of Aryl Tropanyl Esters and Amides Chemically Related to 1H-Indole-3-carboxylic Acid endo 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl Ester”,Arzneimittel Forschung Drug Research, 1993, 43, 913-918.
Kaumann, A., et al., “A 5HT4-like receptor in human right atrium”,Naunyn-Schmiedeberg Arc., Pharmacol. (1991), 344, 150-159.
Cavero, et al., “Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias”,Expert Opinion of Pharmacotherapy, (2000), 1(5): 947-973.
Finlayson, K., et al., “[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen”,European Journal of Pharmacology, 430, (2001), 147-148.
Mutterer, v.F., et al., “Halogenierte Pyridine V. Fluorierte und bromierte Pyridinverbindungen”,Helv. Chim. Acta, (1976), 59, 229-235.
Barlow, M.G., et al., “Diels-Alder reactions of trichloro- 1,2,4-triazine: intramolecular additions with 1,5 and 1,6 dienes1”,J. Chem. Soc., Perkin Trans. I, (1996), 519-524.
Lantos, I., et al., “Novel Cage Compounds from Inter-intra-molecular Diels-Alder Reactions of 1,2,4-Triazines with Cyclo-octa-1,5-diene”,J. Chem. Soc., Chem. Commun. (1998), 1482-1483.
Feibush, B., et al., “Chiral Separation of Heterocyclic Drugs by HPLC: Solute-Stationary Phase Base-Pair Interactions”,J. Am. Chem. Soc., (1986), 108(12), 3310-3318.
G.S. Baxter, et al., “5-Hydroxytryptamine4receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae”,Naunyn-Schmiedeberg's Arch. Pharmacol., (1991), 343, 439-446.
Yukiko Mine, et al., “Comparison of Effect of Mosapride Citrate and Existing 5-HT∝Receptor Agonists on Gastrointestinal Motility In Vivo and In Vitro”,JPET, (1997) 283: 1000-1008.
Reeves, J.J., et al., “Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus”,British Journal of Pharmacology, (1991) 103: 1067-1072.
Z. Zhou, et al., “Properties of HERG Channels Stably Expressed in HEK 293 Cells Studied at Physiological Temperature”,Biophysical Journal, 74, 230-241 (1998).
Lopez-Rodriguez, et al., “Benzimidazole Derivatives. Part 1: Synthesis and Structure-Activity Relationships of New Benzimi9dazole-4-carboxamides and Carboxylates as Potent and Selective 5-HT4 Receptor Antagonists”,Bioorganic&Medicinal Chemistry, 7 (1999), 2271-2281.
Prugh, et la., “A Simple Method of Protecting a Secondary Amine with tert Butyloxycarbonyl (BOC) in the Presence of a Primary Amine”,Synth. Commun., 1992, 22, 2357-60.
Klein, et al., “Design of a New Class of Orally Active Fibrinogen Receptor Antagonists”,J. Med. Chem., 1998, 41, 2492-2502.
Komatsu, et al., “O2-Binding Properties of Double-Sided Porphinairon (II)s with Polar Substituents and Their Human Serum Albumin Hybrids”,Bull. Chem. Soc. Jpn., (2001), 74, 1695-1702.
Iguchi Satoru
Katsu Yasuhiro
Kon-I Kana
Noguchi Hirohide
Uchida Chikara
Benson Gregg C.
Forman Frank W.
Huang Evelyn Mei
Pfizer Inc.
LandOfFree
Imidazopyridine compounds as 5-HT 4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazopyridine compounds as 5-HT 4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazopyridine compounds as 5-HT 4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553932